Xenon Pharmaceuticals XENE
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: −$5.49M (8 inflow days, 12 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 40.3% of shares outstanding.
Largest holders
By investor type
Reported short interest has risen from 5.85% to 7.60% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| T. Rowe Price Group, Inc. | Mutual Fund | 2026/Q3 | +4,568,360 | 10.2% |
| FMR | Mutual Fund | 2026/Q3 | +1,906,450 | 11.8% |
| Capricorn Fund Managers Limited | Hedge Fund | 2026/Q3 | +547,900 | 0.6% |
| Barclays PLC | Public Company | 2026/Q3 | +453,614 | 0.5% |
| Nuveen Asset Management LLC | Insurance Company | 2026/Q3 | +433,471 | 0.7% |
| Pictet Asset Management Limited | Mutual Fund | 2026/Q3 | +280,349 | 1.5% |
| Westfield Capital Management Company, L.P. | Mutual Fund | 2026/Q3 | +271,664 | 1.8% |
| BlackRock | Mutual Fund | 2026/Q3 | +187,931 | 7.8% |
| Morgan Stanley | Public Company | 2026/Q3 | +157,994 | 0.6% |
| Morgan Stanley Investment Management Inc. | Mutual Fund | 2026/Q3 | +157,994 | 0.6% |
| Nuveen Asset Management LLC | Insurance Company | 2026/Q3 | +361,502 | 0.6% |
| FMR | Mutual Fund | 2026/Q3 | +211,810 | 10.2% |
| T. Rowe Price Group, Inc. | Mutual Fund | 2026/Q3 | +3,135,254 | 5.6% |
| BlackRock | Mutual Fund | 2026/Q3 | +1,882,364 | 7.8% |
| Two Sigma Investments, LP | Hedge Fund | 2026/Q3 | +1,036,763 | 1.7% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 14 Oct 2026 | Thomas Kelly | Chief Financial Officer | Derivative Exercise and Retained | +7,500 | – | 22,500 |
| 29 Sep 2026 | Thomas Kelly | Chief Financial Officer | Open Market Acquisition | +15,000 | $37.32 | 15,000 |
| 29 Sep 2026 | Ian Mortimer | Chief Executive Officer | Open Market Acquisition | +30,000 | $37.38 | 64,223 |
| 31 Aug 2026 | Dawn Svoronos | Independent Chairperson | Derivative Exercise and Retained | +5,144 | $8.15 | 31,373 |
| 27 Aug 2026 | Christopher Kenney | Chief Medical Officer | Automatic Disposition | -7,068 | $60.98 | 2 |
| 10 Aug 2026 | Steven Gannon | Independent Director | Open Market Disposition | -10,000 | $64.06 | 1,870 |
| 4 Jun 2026 | Gary Patou | Independent Director | Automatic Disposition | -1,322 | $53.14 | 29,798 |
| 4 Jun 2026 | Gillian Cannon | Independent Director | Automatic Disposition | -1,190 | $53.14 | 1,455 |
| 2 Jun 2026 | Justin Gover | Independent Director | Other Derivative Acquisition | +1,593 | – | 1,593 |
| 2 Jun 2026 | Justin Gover | Independent Director | Other Derivative Acquisition | +10,507 | $53.46 | 10,507 |
| 2 Jun 2026 | Gary Patou | Independent Director | Other Derivative Acquisition | +1,593 | – | 1,593 |
| 2 Jun 2026 | Gary Patou | Independent Director | Other Derivative Acquisition | +10,507 | $53.46 | 10,507 |
| 2 Jun 2026 | C. Machado | Independent Director | Other Derivative Acquisition | +1,593 | – | 1,593 |
| 2 Jun 2026 | C. Machado | Independent Director | Other Derivative Acquisition | +10,507 | $53.46 | 10,507 |
| 2 Jun 2026 | Steven Gannon | Independent Director | Other Derivative Acquisition | +1,593 | – | 1,593 |
| 2 Jun 2026 | Steven Gannon | Independent Director | Other Derivative Acquisition | +10,507 | $53.46 | 10,507 |
| 2 Jun 2026 | Dawn Svoronos | Independent Chairperson | Other Derivative Acquisition | +1,593 | – | 1,593 |
| 2 Jun 2026 | Dawn Svoronos | Independent Chairperson | Other Derivative Acquisition | +10,507 | $53.46 | 10,507 |
| 2 Jun 2026 | Gillian Cannon | Independent Director | Other Derivative Acquisition | +1,593 | – | 1,593 |
| 2 Jun 2026 | Gillian Cannon | Independent Director | Other Derivative Acquisition | +10,507 | $53.46 | 10,507 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 7,363,365 | 7.6% | 6.4 |
| 15 Oct 2026 | 7,348,577 | 7.6% | 4.0 |
| 30 Sep 2026 | 6,041,487 | 6.2% | 1.6 |
| 15 Sep 2026 | 6,444,815 | 6.7% | 12.2 |
| 31 Aug 2026 | 6,344,135 | 6.6% | 9.1 |
| 14 Aug 2026 | 5,668,994 | 5.9% | 9.2 |
No comments yet — be the first to weigh in on XENE.
Sign in to join the discussion.